Survey of Radiosensitizing Agents (Synthesized Chemicals and Gene Therapeutic Agents) Since 2000

Abstract

Key words: radiosensitizing agent, radiosensitizing agent, synthesized chemicals, synthesized chemicals, gene therapy, gene therapy, radiotherapy, radiotherapy, tumor, tumor, cancer, cancer

CLC Number:

R979.1

Supporting:

SHAO Hong^*, LU Jia . Survey of Radiosensitizing Agents (Synthesized Chemicals and Gene Therapeutic Agents) Since 2000[J]. .

[1] Adams J. Preclinical and clinical evaluation of proteasome inhibitor PS-341 for the treatment of cancer [J]. Curr Opin Chem Biol, 2002, 6: 493-500.
[2] Bernhard EJ, Mitchell JB, Deen D, et al. Re-evaluating gadolinium( III) texaphyrin as a radiosensitizing agent [J]. Cancer Res, 2000, 60: 86-91.
[3] Bradbury CM, Markovina S, Wei SJ, et al. Indomethacin-induced radiosensitization and inhibition of ionizing radiation-induced NF-kappaB activation in HeLa cells occur via a mechanism involving p38 MAP kinase [J]. Cancer Res, 2001, 61: 7689-7696.
[4] Busby EC, Leistritz DF, Abraham RT, et al. The radiosensitizing agent 7-hydroxystaurosporine (UCN-01) inhibits the DNA damage checkpoint kinase hChk1 [J]. Cancer Res, 2000, 60: 2108-2112.
[5] Chun YJ, Park IC, Park MJ, et al. Enhancement of radiation response in human cervical cancer cells in vitro and in vivo by arsenic trioxide (As2O3) [J]. FEBS Lett, 2002, 519: 195-200.
[6] Cividalli A, Ceciarelli F, Livdi E, et al. Radiosensitization by oxaliplatin in a mouse adenocarcinoma : influence of treatment schedule [J]. Int J Radiat Oncol Biol Phys, 2002, 52: 1092-1098.
[7] Colletier PJ, Ashoori F, Cowen D, et al. Adenoviral-mediated p53 transgene expression sensitizes both wild-type and null p53 prostate cancer cells in vitro to radiation [J]. Int J Radiat Oncol Biol Phys, 2000, 48: 1507-1512.
[8] Cowen D, Salem N, Ashoori F, et al. Prostate cancer radio-sensitization in vivo with adenovirus-mediated p53 gene therapy [J]. Clin Cancer Res, 2000, 6: 4402-4408.
[9] Curran WJ Jr, Choy H. Optimizing chemoradiation in locally advanced non-small-cell lung cancer [J]. Oncology (Huntingt), 2001, 15: 43-45.
[10] de Lange SM, van Groeningen CJ, Meijer OWM, et al. Gemcitabine-radiotherapy in patients with locally advanced pancreatic cancer [J]. Eur J Cancer, 2002, 38: 1212-1217.
[11] Edgren M, Lennernas B. Estramustine, a radiosensitising agent [J]. Anticancer Res, 2000, 20: 2677-2680.
[12] Eisbruch A, Shewach DS, Bradford CR, et al. Radiation concurrent with gemcitabine for locally advanced head and neck cancer : a phase I trial and intracellular drug incorporation study [J]. J Clin Oncol, 2001, 19: 792-799.
[13] Epelbaum R, Rosenblatt E, Nasrallah S, et al. Phase II study of gemcitabine combined with radiation therapy in patients with localized, unresectable pancreatic cancer [J]. J Surg Oncol, 2002, 81: 138-43.
[14] Fan Z, Chakravarty P, Alfieri A, et al. Adenovirus-mediated antisense ATM gene transfer sensitizes prostate cancer cells to radiation [J]. Cancer Gene Ther, 2000, 7: 1307-1314.
[15] Feng HX, Lu RB, Hu LY, et al. Clinical study and nursing of the radiosensitizing effect of CMNa on nasopharyngeal cancer in radiotherapy [J]. Modern Nursing, 2002, 8: 86-87.
[16] Ferrandina G, Filippini P, Ferlini C, et al. Growth inhibitory effects and radiosensitization induced by fatty aromatic acids on human cervical cancer cells [J]. Oncol Res, 2001, 12: 429-440.
[17] FieldsMT, Eisbruch A, Normolle D, et al. Radiosensitization produced in vivo by once- vs. twice-weekly 2’2’-difluoro-2’-deoxycytidine (gemcitabine) [J]. Int J Radiat Oncol Biol Phys, 2000, 47: 785-791.
[18] Fortunato J E, Mauceri HJ, Kocharyan H, et al. Gene therapy enhances the antiproliferative effect of radiation in intimal hyperplasia [J]. J Surg Res, 2000, 89: 155-162.
[19] Hahn SM, Bernhard EJ, Regine W, et al. A phase I trial of the farnesyltransferase inhibitor L-778,123 and radiotherapy for locally advanced lung and head and neck cancer [J]. Clin Cancer Res, 2002, 8: 1065-1072.
[20] Hui ZG, Li YX, Yang WZ, et al. Abrogation of radiation-induced G2 arrest and radiosensitization by 7-hydroxystauros-porine (UCN-01) in human nasopharyngeal carcinoma cell line [J]. Chin J Cancer, 2003, 22: 6-10.
[21] Kavanagh BD, Khandelwal SR, Schmidt-Ullrich RK, et al. A phase I study of RSR13, a radiation-enhancing hemoglobin modifier : tolerance of repeated intravenous doses and correlation of pharmacokinetics with pharmacodynamics [J]. Int J Radiat Oncol Biol Phys, 2001, 49: 1133-1139.
[22] Lawrence TS, Nyati MK. Small-molecule tyrosine kinase inhibitors as radiosensitizers et al. Semin Radiat Oncol, 2002, 12: 33-36.
[23] Li QL, Peng ZL, Wang H, et al. Effects of cytosine deaminase gene transfer and the combined therapy with radiation in vitro on cervical cancer cells [J]. Pract J Cancer, 2002, 17: 259-262.
[24] Lu WP, Li SY, An P, et al. A study on the radiosensitizing effects of CD/5-FC on rectal cancer cells [J]. Chin J Gen Surg, 2002, 17: 440-441.
[25] Matsuoka H, Shibamoto Y, Kubota T, et al. In vivo efficacy and pharmacokinetics of a new hypoxic cell radiosensitizer doranidazole in SUIT-2 human pancreatic cancer xenografted in mouse pancreas [J]. Oncol Rep, 2000, 7: 23-26.
[26] McKenna WG, Muschel RJ, Gupta AK, et al. Farnesyltransferase inhibitors as radiation sensitizers [J]. Semin Radiat Oncol, 2002, 12: 27-32.
[27] Park SH, Chung YM, Lee YS, et al. Antisense of human peroxiredoxin II enhances radiation-induced cell death [J]. Clin Cancer Res, 2000, 6: 4915-4920.
[28] Rao GS, Murray S, Ethier SP. Radiosensitization of human breast cancer cells by a novel ErbB family receptor tyrosine kinase inhibitor [J]. Int J Radiat Oncol Biol Phys, 2000, 48: 1519-1528.
[29] Rao ZG, Zhang JR, Zheng YF, et al. Radiation sensitizing effect of anti HPV16E6-ribozyme on cervical carcinoma cell line [J]. Chin J Cancer, 2002, 21: 149-152.
[30] Rhomberg W, Jasarevic Z, Alton R, et al. Aggressive angiomyxoma : irradiation for recurrent disease [J]. Strahlenther Onkol, 2000, 176: 324-326.
[31] Rockwell S, Donnelly E-T, Liu YF, et al. Preliminary studies of the effects of gadolinium texaphyrin on the growth and radiosensitivity of EMT6 cells in vitro [J]. Int J Radiat Oncol Biol Phys, 2002, 54: 536-541.
[32] Rosenthal DI, Becerra CR, Toto RD, et al. Reversible renal toxicity resulting from high single doses of the new radiosensitizer gadolinium texaphyrin [J]. Am J Clin Oncol, 2000, 23: 593-598.
[33] Russo SM, Tepper J E, Baldwin ASJr, et al. Enhancement of radiosensitivity by proteasome inhibition : implications for a role of NF-kappaB [J]. Int J Radiat Oncol Biol Phys, 2001, 50: 183-193.
[34] Schaffer M, Schaffer PM, Corti L, et al. Photofrin II as an efficient radiosensitizing agent in an experimental tumor [J]. Onkologie, 2001, 24: 482-485.
[35] Schaffer M, Schaffer PM, Corti L, et al. Photofrin as a specific radiosensitizing agent for tumors : studies in comparison to other porphyrins, in an experimental in vivo model [J]. J Photochem Photobiol B : Biol, 2002, 66: 157-164.
[36] Si JL, Qi YQ, Tao XG, et al. Effects of telomerase inhibitor combined with radiotherapy on gastric cancer in mice [J]. Cancer Res Prev Treat, 2003, 30: 32-33.
[37] Tenzer A, Zingg D, Rocha S, et al. The phosphatidylinositide 3’-kinase/Akt survival pathway is a target for the anticancer and radiosensitizing agent PKC412, an inhibitor of protein kinase C [J]. Cancer Res, 2001, 61: 8203-8210.
[38] Tian H, Wittmack EK, Jorgensen TJ. p21WAF1/CIP1 antisense therapy radiosensitizes human colon cancer by converting growth arrest to apoptosis [J]. Cancer Res, 2000, 60: 679-684.
[39] Wang XP, Yun S, Zhang XL, et al. Primary clinical study of radiosensitizer CMNa [J]. Chin Clin Oncol, 2003, 8: 28-32.
[40] Xiao SW, Zhang SW, Lu YY, et al. Enhancement of radio-sensitivity of human gastric carcinoma cell lines by adenovirus-mediated delivery of the p53 gene [J]. J Peking Univ (Health Sci), 2001, 33: 427-431.
[41] Yang SJ, Zhang XL, Jiang ML, et al. Unusual radiation response of gemcitabine-treated HeLa cells reduced and enhanced survival [J]. Cancer Letters, 2002, 187: 179-183.
[42] Zhang WH, Zhang R, Wu LY, et al. Gemcitabine in advanced and recurrent gynecological malignant tumor : A preliminary analysis [J]. J Oncol, 2002, 8: 193-195.
[43] Zheng XL, Meng XS, Zhao F, et al. The in situ tumor response to radiosensitization a novel sensitizer sodium glycididazole [J]. J Radiat Res Radiat Proces, 2000, 18: 91-95.
[44] Zou C, Guan Y, Zou C, et al. N-(4-hydroxyphenyl) retinamide (4-HPR) modulates GADD45 expression in radiosensitive bladder cancer cell lines [J]. Cancer Lett, 2002, 180: 131-137.

Survey of Radiosensitizing Agents (Synthesized Chemicals and Gene Therapeutic Agents) Since 2000

PDF (PC)

Knowledge

Abstract

Cite this article

share this article

References

Related Articles 15

Recommended Articles

Metrics

Comments

[1]	Gedi Zhang, Gengxin Liu, Ziyou Yan. Therapeutic efficacy evaluation and mechanism of action based on meta-analysis and network pharmacology of Li Chong Decoction (Bolus) for cancer treatment [J]. Journal of Chinese Pharmaceutical Sciences, 2023, 32(9): 720-735.
[2]	Haoxin Du, Qi Bao, Huangqianyu Li, Yichen Zhang, Haishaerjiang Wushouer, Luwen Shi, Xiaodong Guan. Health status of middle-aged and elderly cancer survivors in China [J]. Journal of Chinese Pharmaceutical Sciences, 2023, 32(9): 744-754.
[3]	Wentao Zhu, Wanglong Hong, Miaomiao Zheng, Guoqiang Ma, Aizong Shen. Combination of pembrolizumab and chemotherapy as first-line treatment in advanced triple-negative breast cancer: a cost-effectiveness analysis [J]. Journal of Chinese Pharmaceutical Sciences, 2023, 32(7): 587-597.
[4]	Yancong Zhao, Huiyuan Gong, Jinghua Li. Overexpression of hBD3 inhibits cell proliferation, cell cycle, and migration in colon cancer cells [J]. Journal of Chinese Pharmaceutical Sciences, 2023, 32(4): 250-259.
[5]	Ciyan Peng, Jing Chen, Sini Li, Jianhe Li, Liubao Peng. Evidence-based pharmacoeconomic evaluation of palbociclib in combination with letrozole versus docetaxel in combination with epirubicin in the first-line treatment of advanced breast cancer with epirubicin [J]. Journal of Chinese Pharmaceutical Sciences, 2023, 32(3): 214-222.
[6]	Yuqian Zhang, Haiying Niu, Yiran Jin. Network pharmacology-based strategy to investigate anticancer mechanisms of Catharanthus roseus (L.) G. Don [J]. Journal of Chinese Pharmaceutical Sciences, 2023, 32(11): 911-922.
[7]	Kai Li, Bingjie Tang, Xinlong Chai, Yang Ping, Lihong Wang, Jin Su. Sialic acid-functionalized targeted drug delivery systems: advances in tumor and inflammation therapy by binding to Siglecs or selectin receptors [J]. Journal of Chinese Pharmaceutical Sciences, 2023, 32(10): 773-795.
[8]	Ning Ding, Tao Zhang, Ji Luo, Haochen Liu, Yu Deng, Yongheng He. Study on the mechanism of Baishao Qiwu Decoction in the treatment of colorectal cancer based on network pharmacology and molecular docking [J]. Journal of Chinese Pharmaceutical Sciences, 2023, 32(1): 17-31.
[9]	Neha Dangi, Shikha Sharma. Cancer chemotherapy with novel bioactive natural products [J]. Journal of Chinese Pharmaceutical Sciences, 2022, 31(8): 589-607.
[10]	Weiping Zhao, Qi Ge, Zijun Ding, Leizhi Pan, Ziqing Gu, Yang Liu, Hua Cai. Network pharmacology and metabolomics-based detection of the potential pharmacological effects of the active components in Chrysanthemum morifolium 'Chuju' [J]. Journal of Chinese Pharmaceutical Sciences, 2022, 31(6): 412-428.
[11]	Jianwei Dong, Xuejiao Li, Chen Yang, Yanqing Zhang, Huifang Zhou, Yali Li. The antioxidant activity and total phenolic and total flavonoid contents of Pyracantha fortuneana fruit can be improved by solid-state fermentation with Rhizopus oryzae and Penicillium commune [J]. Journal of Chinese Pharmaceutical Sciences, 2022, 31(6): 452-460.
[12]	Liangyu Liu, Yuke Yang, Xiao Du, Tong Wu, Jiannong Wang. Three previously undescribed steroidal glycoalkaloids from Solanum lyratum and their anti-tumor activities [J]. Journal of Chinese Pharmaceutical Sciences, 2022, 31(3): 192-201.
[13]	Eric Wei Chiang Chan, Siu Kuin Wong, Hung Tuck Chan. Genipin and geniposide from Gardenia jasminoides: An overview of their anti-cancer and other pharmacological properties [J]. Journal of Chinese Pharmaceutical Sciences, 2022, 31(1): 1-12.
[14]	Shiqi Xu, Liyan Zhu, Chao Hao, Wenqian Liu, Chenglong Chen, Yongyi Chen, Aiqin Liu. Synthesis of a novel series of amino acid prodrugs based on tegafur and evaluation of their antitumor activity [J]. Journal of Chinese Pharmaceutical Sciences, 2021, 30(9): 743-753.
[15]	Cong Huang, Carolina Oi Lam Ung, Haishaerjiang Wushouer, Ziyue Xu, Yichen Zhang, Xiaodong Guan, Luwen Shi. The impact of the provincial reimbursement scheme on the use of targeted anticancer medications in Zhejiang, China: a controlled interrupted time-series analysis [J]. Journal of Chinese Pharmaceutical Sciences, 2021, 30(7): 590-597.